Foghorn Short Long Term Debt Total from 2010 to 2024

FHTX Stock  USD 7.90  0.06  0.77%   
Foghorn Therapeutics Short and Long Term Debt Total yearly trend continues to be fairly stable with very little volatility. Short and Long Term Debt Total is likely to outpace its year average in 2024. During the period from 2010 to 2024, Foghorn Therapeutics Short and Long Term Debt Total regression line of annual values had r-squared of  0.56 and arithmetic mean of  24,304,562. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
2010-12-31
Previous Quarter
45.1 M
Current Value
47.8 M
Quarterly Volatility
25.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Foghorn Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Foghorn Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 11.1 M, Interest Income of 11.1 M or Depreciation And Amortization of 3.9 M, as well as many indicators such as Price To Sales Ratio of 7.53, Dividend Yield of 0.0 or Days Sales Outstanding of 66.4 K. Foghorn financial statements analysis is a perfect complement when working with Foghorn Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Foghorn Therapeutics Correlation against competitors.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Latest Foghorn Therapeutics' Short Long Term Debt Total Growth Pattern

Below is the plot of the Short Long Term Debt Total of Foghorn Therapeutics over the last few years. It is Foghorn Therapeutics' Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Foghorn Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt Total10 Years Trend
Slightly volatile
   Short Long Term Debt Total   
       Timeline  

Foghorn Short Long Term Debt Total Regression Statistics

Arithmetic Mean24,304,562
Geometric Mean14,830,984
Coefficient Of Variation104.05
Mean Deviation21,754,083
Median7,029,000
Standard Deviation25,288,388
Sample Variance639.5T
Range75M
R-Value0.75
Mean Square Error302.8T
R-Squared0.56
Significance0
Slope4,232,704
Total Sum of Squares8953T

Foghorn Short Long Term Debt Total History

202447.8 M
202345.1 M
202251.5 M
202158.3 M
202082 M
201916.6 M

About Foghorn Therapeutics Financial Statements

Foghorn Therapeutics investors use historical fundamental indicators, such as Foghorn Therapeutics' Short Long Term Debt Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Foghorn Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short and Long Term Debt Total45.1 M47.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.